HT-KIT reduced tumor size by day 8 and showed no organ toxicity in preclinical studies. The candidate remained stable in serum for 37 days at -80°C, exceeding benchmarks. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) Hoth Therapeutics Inc.

100% of patients in the trial achieved an ARIGA score ≤1, showing significant skin toxicity improvements by six weeks. 66% reported reduced pain and itching, enhancing quality of life while maintaining full EGFRi dosages. On Tuesday, Hoth Therapeutics, Inc.